$CTOR surged a massive 17% today! Many members in the group jumped on my latest recommendation and are already cashing in big time. Didn’t catch it? Don’t worry. Just tap my profile, add me on WhatsApp, and message “2”. Fresh premium stock picks every day! #Investing#Trading #Finance #WallStreet #FinancialFreedom
Insiders are taking profits on $C* as volatility spikes between 10% and 50%. If you want to stay ahead of the move, join the inner circle. Add us on WhatsApp from the homepage right now. Benefits: Entry ranges, stop-loss levels, and live sell signals #Stocks#Investing#Trading #Finance #WallStreet #FinancialFreedom
$IBRX: ANKTIVA reported first-quarter revenue of $44.2 million, a 168% year-over-year increase, with cash on hand of $381 million. Business momentum remains strong. Nevertheless, the U.S. Food and Drug Administration (FDA) warning letter and class-action lawsuits continue to weigh on short-term market sentiment. In my view, the market has overreacted. Management has addressed the issues promptly, approved indications remain unchanged, and long-term fundamentals remain solid.
Consensus Target Price: $14.40–$14.80, with nearly 100% upside potential. Weekly Outlook: Moderately bullish, range-bound. Expected trading range for next week: $7.00–$8.50. The strong rebound in volume on April 9 indicates a return of buying interest. Barring new negative news, the stock should easily test above $8.00.
Trading Reference Levels:
Entry: Buy on a pullback to $7.00–$7.40—build positions in increments if volume confirms the trend.
Take Profit: $8.20–$8.80—take profits by reducing positions at appropriate times.
Stop Loss: Below $6.50—exit promptly to protect capital.
Biotech stocks are highly volatile. While capitalizing on opportunities, be sure to manage risk effectively. This article represents my independent analysis only and does not constitute investment advice.
#SNDK #FinancialFreedom
$NVAX Relative Strength Index (RSI) has plunged deep into oversold territory, while the negative divergence in the Moving Average Convergence Divergence (MACD) has finally begun to narrow, indicating that short-term technical conditions are gradually improving. From a fundamental perspective, I maintain my previous view: fourth-quarter earnings once again exceeded expectations, and milestone progress in the collaboration with Sanofi/Pfizer is providing support for the company.
However, revenue in 2026 could still be halved—the growing pains of the transition are not yet over. Given the lack of major catalysts in the near term, the true test will be the first-quarter earnings report scheduled for release on May 7.
My personal outlook for next week: The most likely scenario is a slight rebound amid volatility, with a trading range of approximately $8.00–$9.00.
The best entry point is a pullback to the $8.00–$8.20 range—wait for volume confirmation before adding to your position.
Considering taking profits? Reduce half of your position in the $8.80–$9.00 range; if the price breaks above $9.20, you can add a small position on the way up.
Stop-loss: Exit immediately if the price falls below $7.70—keep risk within 8%–10%. Frankly, the current valuation is extremely attractive (P/E ratio of just 3x), but the volatility is simply too extreme.
Is anyone currently holding NVAX? Are you planning to buy on the dip, or are you choosing to sit on the sidelines? Please leave a comment below to share your thoughts.
#NVAX #USStocks #SwingTrading #Biotech
Pre-market movers revealed: Constellation Brands, Datadog, Occidental, CoreWeave, and others lead the gains
Several stocks are showing unusual trading activity in pre-market trading today, with companies in the alcohol, data analytics, energy, and AI infrastructure sectors performing particularly well. Investors are closely watching specific companies’ earnings reports and industry catalysts.
The Wall Street Journal says Iran now requires ships passing through the Strait of Hormuz to pay tolls using either cryptocurrency or the Chinese yuan.
Everyone, NCNO has indeed staged a strong rally over the past few days. After the market closed yesterday, I reviewed the earnings report, the newly launched AI products, and the stock chart once again, and my conclusions are even more optimistic than the market consensus.
It’s no longer news that Q4 and full-year results exceeded expectations, but what really caught my attention was: ACV achieved 13% organic growth, net retention reached 112%, non-GAAP operating margins improved significantly, and free cash flow grew by 55% year-over-year. More importantly, on the day the earnings report was released, the company immediately announced the launch of a $1 billion accelerated share repurchase program; On April 6, it swiftly launched the “Analyst Digital Partner” AI tool, which can reduce commercial credit review times by 70%. This is by no means an empty promise on a slide—it is a tangible AI implementation backed by strong cash flow, and management’s execution capabilities have clearly reached new heights. The stock price surged from $14.98 on earnings day to $18.02 yesterday, with significantly increased trading volume, marking a 20% gain in just five trading days. As trading volume continues to expand, the technical picture has shifted from a bottoming-out phase to a short-term bullish pattern.
The $17.20–$17.50 range represents the optimal entry point for adding to positions—this range lies within a recent area of active trading and features solid support.
#NVDA #TSLA
Popular stocks like Tesla (TSLA) continue to lead the trading volume charts
Stocks such as TSLA and CrowdStrike (CRWD) are generating significant buzz on Yahoo Finance and Stocktwits, drawing the attention of both retail and institutional investors.
From what I’m seeing on the CL oil chart so far, I reckon there’s still space for it to push ahead in the next week or two — just my take
#FinancialFreedom#Finance
$ENVX Enovix is the pioneer in silicon-anode lithium-ion batteries, delivering breakthrough energy density—AI-1 cells already hitting 935 Wh/L and certified for smartphones, wearables, and defense
Key tailwinds: record 2025 revenue up 38% YoY, fresh $75M buyback authorization, and improving cash burn. Wall Street’s consensus target sits north of $13 (100%+ upside), with several calling for $25 long-term
Short-term technicals look constructive for a rebound
buy $5.00–$5.30 zone.
Target $6.50–$7.00 near-term.
Hard stop below $4.80.
Attractive risk/reward for growth investors in next-gen battery tech
UnitedHealth (UNH) and other defensive names dominate trending lists
Yahoo Finance’s most-active stocks show investors rotating into defensive large-caps like UNH and AVGO amid ongoing uncertainty
WTI Crude has just slid 4% off its intraday high and is now trading under $112 as Trump’s 8 p.m. deadline draws near.U.S. futures have flipped positive as well
Three possible scenarios are in play
DEAL AND CEASEFIRE: Oil would plunge sharply while equities stage a strong rally. This is exactly what the market appears to be pricing in at the moment.
ANOTHER EXTENSION: Oil remains choppy with no major breakdown. The uncertainty premium lingers in the price, setting up yet another week of the same pattern
NO DEAL, WAR CONTINUES: Oil launches a fresh rally and equities sell off hard. This is the outcome that nobody is currently factoring into prices
Iran just dropped a bomb: Strait of Hormuz closed long-term to US & Israel.
Result? WTI Crude closed at $111.03 — highest since June 2022. Oil is on fire
Insiders are taking profits on $C* as volatility spikes between 10% and 50%. If you want to stay ahead of the move, join the inner circle. Add us on WhatsApp from the homepage right now. Benefits: Entry ranges, stop-loss levels, and live sell signals #Stocks#Investing#Trading #Finance #WallStreet #FinancialFreedom
$KOD Kodiak Sciences isn’t your typical clinical-stage story — it’s a platform company with a real shot at transforming retinal disease treatment. Their lead asset Zenkuda just crushed the GLOW2 Phase 3 readout: statistically superior efficacy in diabetic retinopathy, convenient 6-month dosing, and a pristine safety profile with zero intraocular inflammation. That’s a clear competitive edge
The stock exploded higher on massive volume after the data and earnings, confirming the market is finally pricing in the upside. Pipeline momentum is building fast across multiple late-stage trials, and the Street’s Strong Buy consensus with targets north of $50 tells you the re-rating has legs.Technicals look textbook: clean breakout, strong MA alignment, and momentum still intact
Buy: $39–40 (dip-buy zone)
Target: $45–48 (next resistance)
Stop: $35 (invalidates the setup)
de-risked clinical data, massive commercial potential, and a fresh technical breakout
#Investing
#Trading
#Finance
#WallStreet
#NVDA
#FinancialFreedom
S&P 500 and Nasdaq Slide as Tech Selling Intensifies
Early April selling pressure in technology names pushed the S&P 500 back toward 6,882 and sent the Nasdaq down more than 1%
Another trading day ends… and our group walks away with clean profits. We didn’t chase the pump. We didn’t panic when it dipped. We simply followed the plan with an edge. That’s the difference between gamblers and professionals. Ready to trade like a pro? Click my profile, add WhatsApp, send “2”
#FinTwit #StockMarket #Stocks #Investing #Trading #FinancialFreedom